Abstract
Ebola Virus Disease (EVD) is a severe, often fatal zoonotic disease caused by viruses of the genus Ebolavirus (family Filoviridae). It is characterized by hemorrhagic fever, gastrointestinal symptoms, multi-organ dysfunction, and shock, with mortality reaching up to 90% in some Zaire ebolavirus infections. Fruit bats of the family Pteropodidae are considered the natural reservoir, with transmission occurring through direct contact with infected animals or human bodily fluids. Human-to-human transmission is the primary route during outbreaks. Viral proteins such as GP, VP24, and VP35 contribute to immune evasion and disease progression. Diagnosis involves RT-PCR and serological assays such as ELISA. Although supportive care remains essential, approved therapeutics, including Inmazeb and Ebanga, have improved treatment outcomes. The rVSV-ZEBOV (Ervebo) vaccine provides effective protection. A One Health approach integrating human, animal, and environmental health is crucial for surveillance, prevention, preparedness, and global outbreak control.
The full text of this article is available as a PDF.
Download PDF- 1. Baize, S., Leroy, E. M., Georges-Courbot, M. C., Capron, M., Lansoud-Soukate, J., Debre, P., Fisher-Hoch, S. P., McCormick, J. B., & Georges, A. J. (2009). Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. Nature Medicine, 5(4), 423–426.
- 2. Baize, S., Leroy, E. M., Georges, A. J., Georges-Courbot, M. C., Capron, M., Bedjabaga, I., et al. (2002). Inflammatory responses in Ebola virus-infected patients. Clinical & Experimental Immunology, 128(1), 163–168.
- 3. Banadyga, L., Zhu, W., Kailasan, S., Howell, K. A., Franaszek, K., He, S., Siragam, V., Cheng, K., Yan, F., Moffat, E., & Cao, W. (2021). Atypical Ebola virus disease in a nonhuman primate following monoclonal antibody treatment is associated with glycoprotein mutations within the fusion loop. mBio, 12(1), 10–1128.
- 4. Basler, C. F. (2017). Molecular pathogenesis of viral hemorrhagic fever. Seminars in Immunopathology, 39(5), 551–561.
- 5. Beeching, N. J., Fenech, M., & Houlihan, C. F. (2014). Ebola virus disease. BMJ, 349.
- 6. Bharat, T. A., Noda, T., Riches, J. D., Kraehling, V., Kolesnikova, L., Becker, S., Kawaoka, Y., & Briggs, J. A. (2012). Structural dissection of Ebola virus and its assembly determinants using cryo-electron tomography. Proceedings of the National Academy of Sciences, 109(11), 4275–4280.
- 7. Bornholdt, Z. A., Turner, H. L., Murin, C. D., Li, W., Sok, D., Souders, C. A., Piper, A. E., Goff, A., Shamblin, J. D., Wollen, S. E., & Sprague, T. R. (2016). Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science, 351(6277), 1078–1083.
- 8. Bray, M., & Geisbert, T. W. (2005). Ebola virus: The role of macrophages and dendritic cells in the pathogenesis of Ebola hemorrhagic fever. The International Journal of Biochemistry & Cell Biology, 37(8), 1560–1566.
- 9. Briand, S., Bertherat, E., Cox, P., Formenty, P., Kieny, M. P., Myhre, J. K., Roth, C., Shindo, N., & Dye, C. (2014). The international Ebola emergency. New England Journal of Medicine, 371, 1180–1183.
- 10. Broadhurst, M. J., Brooks, T. J., & Pollock, N. R. (2016). Diagnosis of Ebola virus disease: Past, present, and future. Clinical Microbiology Reviews, 29(4), 773–793.
- 11. Chertow, D. S., Kleine, C., Edwards, J. K., Scaini, R., Giuliani, R., & Sprecher, A. (2014). Ebola virus disease in West Africa: Clinical manifestations and management. New England Journal of Medicine, 371(22), 2054–2057.
- 12. Coltart, C. E., Lindsey, B., Ghinai, I., Johnson, A. M., & Heymann, D. L. (2017). The Ebola outbreak, 2013–2016: Old lessons for new epidemics. Philosophical Transactions of the Royal Society B: Biological Sciences, 372(1721), 20160297.
- 13. de La Vega, M. A., Caleo, G., Audet, J., Qiu, X., Kozak, R. A., Brooks, J. I., Kern, S., Wolz, A., Sprecher, A., Greig, J., & Lokuge, K. (2015). Ebola viral load at diagnosis associates with patient outcome and outbreak evolution. The Journal of Clinical Investigation, 125(12), 4421–4428.
- 14. Diallo, B., Sissoko, D., Loman, N. J., Bah, H. A., Bah, H., Worrell, M. C., Conde, L. S., Sacko, R., Mesfin, S., Loua, A., & Kalonda, J. K. (2016). Resurgence of Ebola virus disease in Guinea linked to a survivor with virus persistence in seminal fluid for more than 500 days. Clinical Infectious Diseases, 63(10), 1353–1356.
- 15. Feldmann, H., & Geisbert, T. W. (2011). Ebola haemorrhagic fever. The Lancet, 377(9768), 849–862.
- 16. Feldmann, H., Jones, S., Klenk, H. D., & Schnittler, H. J. (2003). Ebola virus: From discovery to vaccine. Nature Reviews Immunology, 3(8), 677–685.
- 17. Feldmann, H., Klenk, H. D., & Sanchez, A. (1993). Molecular biology and evolution of filoviruses. Unconventional Agents and Unclassified Viruses: Recent Advances in Biology and Epidemiology, 81–100.
- 18. Franchini, M. (2021). Convalescent plasma therapy for managing infectious diseases: A narrative review. Annals of Blood, 6.
- 19. Geisbert, T. W., Strong, J. E., & Feldmann, H. (2015). Considerations in the use of nonhuman primate models of Ebola virus and Marburg virus infection. The Journal of Infectious Diseases, 212(Suppl. 2), 91–97.
- 20. Gupta, M., Mahanty, S., Greer, P., Towner, J. S., Shieh, W.-J., Zaki, S. R., Ahmed, R., & Rollin, P. E. (2004). Persistent infection with Ebola virus under conditions of partial immunity. Journal of Virology, 78(2), 958–967.
- 21. Gupta, R. (2014). Rethinking the development of Ebola treatments. The Lancet Global Health, 2(10), 563–564.
- 22. Haasnoot, J., de Vries, W., Geutjes, E. J., Prins, M., & Berkhout, B. (2007). The Ebola virus VP35 protein is a suppressor of RNA silencing. PLoS Pathogens, 3(6), e86.
- 23. Halfmann, P. J., Eisfeld, A. J., Watanabe, T., Maemura, T., Yamashita, M., Fukuyama, S., Armbrust, T., Rozich, I., N’jai, A., Neumann, G., & Kawaoka, Y. (2019). Serological analysis of Ebola virus survivors and close contacts in Sierra Leone: A cross-sectional study. PLoS Neglected Tropical Diseases, 13(8), e0007654.
- 24. Hartman, A. L., Towner, J. S., & Nichol, S. T. (2004). A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus. Virology, 328(2), 177–184.
- 25. Henao-Restrepo, A. M., Camacho, A., Longini, I. M., Watson, C. H., Edmunds, W. J., Egger, M., & Kieny, M. P. (2017). Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: Final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). The Lancet, 389(10068), 505–518.
- 26. Jacob, S. T., Crozier, I., Fischer, W. A., Hewlett, A., Kraft, C. S., Vega, M. A. D. L., Soka, M. J., Wahl, V., Griffiths, A., Bollinger, L., & Kuhn, J. H. (2020). Ebola virus disease. Nature Reviews Disease Primers, 6(1), 13.
- 27. Jaspard, M., Mulangu, S., Juchet, S., Serra, B., Dicko, I., Lang, H. J., Baka, B. M., Komanda, G. M., Katsavara, J. M., Kabuni, P., & Mambu, F. M. (2022). Development of the PREDS score to predict in-hospital mortality of patients with Ebola virus disease under advanced supportive care: Results from the EVISTA cohort in the Democratic Republic of the Congo. EClinicalMedicine, 54.
- 28. Lee, J. E., Fusco, M. L., Hessell, A. J., Oswald, W. B., Burton, D. R., & Saphire, E. O. (2008). Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature, 454(7201), 177–182.
- 29. Leitenberg, M. (2005). Assessing the biological weapons and bioterrorism threat. DIANE Publishing.
- 30. Leroy, E. M., Kumulungui, B., Pourrut, X., Rouquet, P., Hassanin, A., Yaba, P., & Swanepoel, R. (2005). Fruit bats as reservoirs of Ebola virus. Nature, 438(7068), 575–576.
- 31. Letafati, A., Ardekani, O. S., Karami, H., & Soleimani, M. (2023). Ebola virus disease: A narrative review. Microbial Pathogenesis, 181, 106213.
- 32. Liu, Y., Sun, Y., Wu, W., Li, A., Yang, X., Zhang, S., Li, C., Su, Q., Cai, S., Sun, D., & Hu, H. (2018). Serological investigation of laboratory-confirmed and suspected Ebola virus disease patients during the late phase of the Ebola outbreak in Sierra Leone. Virologica Sinica, 33(4), 323–334.
- 33. Mani, V., Chu, W. T., Yang, H. J., Morris, C. P., Laux, J., Byrum, R., Cooper, K., Liu, D. X., Wang, H., Johnson, C., & Hadley, K. (2025). Reactive oxygen species-related oxidative changes are associated with splenic lymphocyte depletion in Ebola virus infection. npj Imaging, 3(1), 16.
- 34. Martines, R. B., Ng, D. L., Greer, P. W., Rollin, P. E., & Zaki, S. R. (2015). Tissue and cellular tropism, pathology and pathogenesis of Ebola and Marburg viruses. The Journal of Pathology, 235(2), 153–174.
- 35. Mbala-Kingebeni, P., Aziza, A., Di Paola, N., Wiley, M. R., Makiala-Mandanda, S., Caviness, K., Pratt, C. B., Ladner, J. T., Kugelman, J. R., Prieto, K., & Chitty, J. A. (2019). Medical countermeasures during the 2018 Ebola virus disease outbreak in the North Kivu and Ituri Provinces of the Democratic Republic of the Congo: A rapid genomic assessment. The Lancet Infectious Diseases, 19(6), 648–657.
- 36. McElroy, A. K., Akondy, R. S., McIlwain, D. R., Chen, H., Bjornson-Hooper, Z., Mukherjee, N., & Spiropoulou, C. F. (2020). Immunologic timeline of Ebola virus disease and recovery in humans. JCI Insight, 5(10), e137260.
- 37. Meakin, S., Nsio, J., Camacho, A., Kitenge, R., Coulborn, R. M., Gignoux, E., Johnson, J., Sterk, E., Musenga, E. M., Mustafa, S. H. B., & Finger, F. (2024). Effectiveness of rVSV-ZEBOV vaccination during the 2018–20 Ebola virus disease epidemic in the Democratic Republic of the Congo: A retrospective test-negative study. The Lancet Infectious Diseases, 24(12), 1357–1365.
- 38. Mehedi, M., Falzarano, D., Seebach, J., Hu, X., Carpenter, M. S., Schnittler, H. J., & Feldmann, H. (2011). A new Ebola virus nonstructural glycoprotein expressed through RNA editing. Journal of Virology, 85(11), 5406–5414.
- 39. Messaoudi, I., Amarasinghe, G. K., & Basler, C. F. (2015). Filovirus pathogenesis and immune evasion: Insights from Ebola virus and Marburg virus. Nature Reviews Microbiology, 13(11), 663–676.
- 40. Miller, E. H., Obernosterer, G., Raaben, M., Herbert, A. S., Deffieu, M. S., Krishnan, A., & Chandran, K. (2012). Ebola virus entry requires the host-programmed recognition of an intracellular receptor. Science, 309(5731), 1576–1579.
- 41. Mire, C. E., Cross, R. W., Geisbert, J. B., Borisevich, V., Agans, K. N., Deer, D. J., Heinrich, M. L., Rowland, M. M., Goba, A., Momoh, M., Boisen, M. L., Grant, D. S., Fullah, M., Khan, S. H., Fenton, K. A., Robinson, J. E., Branco, L. M., Garry, R. F., Geisbert, T. W., & Geisbert, J. B. (2015). Single-dose attenuated Vesiculovax vaccines protect primates against Ebola Makona virus. Nature, 520(7549), 688–691.
- 42. Muhlberger, E., Weik, M., Volchkov, V. E., Klenk, H. D., & Becker, S. (1999). Comparison of the transcription and replication strategies of Marburg virus and Ebola virus by using artificial replication systems. Journal of Virology, 73(3), 2333–2342.
- 43. Mulangu, S., Dodd, L. E., Davey, R. T., Jr., Tshiani Mbaya, O., Proschan, M., Mukadi, D., & Muyembe-Tamfum, J. J. (2019). A randomized, controlled trial of Ebola virus disease therapeutics. New England Journal of Medicine, 381(24), 2293–2303.
- 44. Osterholm, M. T., Moore, K. A., Kelley, N. S., Brosseau, L. M., Wong, G., Murphy, F. A., & Kobinger, G. P. (2015). Transmission of Ebola viruses: What we know and what we do not know. mBio, 6(2), 10–1128.
- 45. Pallesen, J., Murin, C. D., De Val, N., Cottrell, C. A., Hastie, K. M., Turner, H. L., Fusco, M. L., Flyak, A. I., Zeitlin, L., Crowe, J. E., & Andersen, K. G. (2016). Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nature Microbiology, 1(9), 16128.
- 46. Ravichandran, S., & Khurana, S. (2022). Ebola-Detect: A differential serodiagnostic assay for Ebola virus infections and surveillance in the presence of vaccine-induced antibodies. EBioMedicine, 82.
- 47. Reid, S. P., Leung, L. W., Hartman, A. L., Martinez, O., Shaw, M. L., Carbonnelle, C., & Basler, C. F. (2006). Ebola virus VP24 binds karyopherin α1 and blocks STAT1 nuclear accumulation. Journal of Virology, 80(11), 5156–5167.
- 48. Rijal, P., Elias, S. C., Machado, S. R., Xiao, J., Schimanski, L., O’Dowd, V., et al. (2019). Therapeutic monoclonal antibodies for Ebola virus infection derived from vaccinated humans. Cell Reports, 27(1), 172–186.
- 49. Rivera, A., & Messaoudi, I. (2015). Pathophysiology of Ebola virus infection: Current challenges and future hopes. ACS Infectious Diseases, 1(5), 186–197.
- 50. Schnittler, H. J., & Feldmann, H. (2003). Viral hemorrhagic fever—a vascular disease? Thrombosis and Haemostasis, 89(6), 967–972.
- 51. Sissoko, D., Duraffour, S., Kerber, R., Kolie, J. S., Beavogui, A. H., Camara, A. M., Colin, G., Rieger, T., Oestereich, L., Pályi, B., & Wurr, S. (2017). Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: A longitudinal analysis and modelling study. The Lancet Global Health, 5(1), 80–88.
- 52. Sissoko, D., Keïta, M., Diallo, B., Aliabadi, N., Fitter, D. L., Dahl, B. A., Akoi Bore, J., Raymond Koundouno, F., Singethan, K., Meisel, S., & Enkirch, T. (2017). Ebola virus persistence in breast milk after no reported illness: A likely source of virus transmission from mother to child. Clinical Infectious Diseases, 64(4), 513–516.
- 53. Sivanandy, P., Jun, P. H., Man, L. W., Wei, N. S., Mun, N. F. K., Yii, C. A. J., & Ying, C. C. X. (2022). A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020. Journal of Infection and Public Health, 15(3), 285–292.
- 54. Sullivan, N. J., Hensley, L., Asiedu, C., Geisbert, T. W., Stanley, D., Johnson, J., & Goudsmit, J. (2011). CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nature Medicine, 17(9), 1128–1131.
- 55. Sullivan, N. J., Martin, J. E., Graham, B. S., & Nabel, G. J. (2009). Correlates of protective immunity for Ebola vaccines: Implications for regulatory approval by the animal rule. Nature Reviews Microbiology, 7(5), 393–400.
- 56. Sullivan, N. J., Yang, Z. Y., & Nabel, G. J. (2003). Ebola virus pathogenesis: Implications for vaccines and therapies. Journal of Virology, 77(18), 9733–9737.
- 57. Wan, W., Kolesnikova, L., Clarke, M., Koehler, A., Noda, T., Becker, S., & Briggs, J. A. (2017). Structure and assembly of the Ebola virus nucleocapsid. Nature, 551(7680), 394–397.
- 58. Warfield, K. L., Alves, D. A., Bradfute, S. B., Reed, D. K., VanTongeren, S., Kalina, W. V., & Bavari, S. (2007). Development of a model for Marburgvirus based on severe-combined immunodeficiency mice. Virology Journal, 4, 1–13.
- 59. Wauquier, N., Padilla, C., Becquart, P., Leroy, E., & Vieillard, V. (2010). Association of KIR2DS1 and KIR2DS3 with fatal outcome in Ebola virus infection. Immunogenetics, 62(11), 767–771.
- 60. Weik, M., Modrof, J., Klenk, H. D., Becker, S., & Muhlberger, E. (2002). Ebola virus VP30-mediated transcription is regulated by RNA secondary structure formation. Journal of Virology, 76(17), 8532–8539.
- 61. World Health Organization. (2020). Ebola virus disease. https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
- 62. World Health Organization. (2021). Ebola virus disease: Treatment. https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
- 63. World Health Organization. (2022). Ebola virus disease. https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
- 64. Woolsey, C., & Geisbert, T. W. (2021). Current state of Ebola virus vaccines: A snapshot. PLoS Pathogens, 17(12), e1010078.
- 65. World Health Organization. (2021). Ebola virus disease: Key facts. https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
- 66. Yang, Z. Y., Delgado, R., Xu, L., Todd, R. F., Nabel, E. G., Sanchez, A., & Nabel, G. J. (1998). Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins. Science, 279(5353), 1034–1037.
- 67. Zhang, A. P. P., Bornholdt, Z. A., Liu, T., Abelson, D. M., Lee, D. E., Li, S., Woods, V. L., Jr., & Saphire, E. O. (2012). The Ebola virus interferon antagonist VP24 directly binds STAT1 and has a novel, pyramidal fold. PLoS Pathogens, 8(2), e1002550.
Looking up citing articles…
Copyright © 2026 Journal of Veterinary and Life Sciences